Caas Capital Management LP Gilead Sciences, Inc. Transaction History

Caas Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $1.13 Million - $1.42 Million	-19,500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $1.04 Million - $1.19 Million	-16,100 Reduced 45.22%	19,500 $1.42 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $500,906 - $540,422	7,400 Added 26.24%	35,600 $2.49 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $368,126 - $402,229	-5,800 Reduced 17.06%	28,200 $1.94 Million
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $1.93 Million - $2.19 Million	34,000 New	34,000 $1.98 Million

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.